Recombinant Cyprinus carpio cyp c 1.02 Protein ，His & SUMO

CYP C 1.02, a member of the cytochrome P450 family, has garnered significant attention in pharmacological and biochemical research due to its pivotal role in drug metabolism and biotransformation processes. The cytochrome P450 enzymes are integral to the oxidative metabolism of a wide variety of substrates, including pharmaceuticals, environmental pollutants, and endogenous compounds. This particular isoenzyme is notable for its unique substrate specificity and catalytic efficiency, which can vary significantly across different species and individual organisms. Understanding CYP C 1.02 is critical for elucidating its involvement in detoxification pathways and the metabolic clearance of therapeutic agents, thus providing insights into drug-drug interactions and individual variability in drug responses. Additionally, given the increasing prevalence of polymorphisms and mutations in drug-metabolizing enzyme genes, research on CYP C 1.02 also holds promise for personalized medicine approaches, allowing for the optimization of treatment regimens based on an individual's metabolic profile. Studies have demonstrated that alterations in CYP C 1.02 activity can lead to significant pharmacokinetic changes, impacting drug efficacy and safety. Consequently, ongoing investigations aim to characterize the substrate specificity, expression patterns, and regulatory mechanisms of CYP C 1.02, contributing to the broader understanding of its functional role in human health and disease. The findings from such research may also inform the development of new therapeutic agents and strategies for minimizing adverse drug reactions. Overall, the study of CYP C 1.02 is essential for advancing our knowledge of metabolic enzymes and their implications in pharmacotherapy and toxicology.